GO-M100B / GO Therap - LARVOL DELTA

Targeting tumor-specific Tn-glycoforms of MUC1 and MUC4 with first-in-class antibody-drug conjugates: Preclinical efficacy and translational potential of GO-M100B and GO-M400 (AACR 2026) - "By targeting cancer-specific glycosylation patterns on mucins, M100B and M400 expand the therapeutic frontier of "clean target" oncology. These next-generation ADCs demonstrate exceptional tumor selectivity, strong preclinical efficacy, and favorable safety, supporting advancement into IND-enabling studies and clinical development for multiple epithelial malignancies."

ADC • Preclinical • Oncology • Solid Tumor • MUC1 • MUC4